论文部分内容阅读
目的探讨和比较瑞舒伐他汀与辛伐他汀对高龄患者高脂血症治疗的临床效果差异。方法选择于2010年5月至2012年5月期间收治的200例高龄高脂血症患者作为研究对象,分为瑞舒伐他汀组和辛伐他汀组,每组各100例,其中瑞舒伐他汀组按照使用说明服用瑞舒伐他汀药物,辛伐他汀组则按照使用说明服用辛伐他汀药物,疗程8周,于治疗前后测定血浆总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)水平及肝肾功能。结果治疗8周之后,瑞舒伐他汀组显效38例,有效54例,无效8例,总有效率为92.0%;辛伐他汀组显效30例,有效50例,无效20例,总有效率为80.0%。两组患者的降脂总有效率比较差异有统计学意义(P<0.05)。结论瑞舒伐他汀较辛伐他汀降脂作用更为显著,不良反应相仿,具有较高的临床应用价值。
Objective To investigate and compare the clinical effects of rosuvastatin and simvastatin in the treatment of elderly patients with hyperlipidemia. Methods From May 2010 to May 2012, 200 cases of elderly patients with hyperlipidemia were selected as study subjects and divided into rosuvastatin group and simvastatin group, with 100 cases in each group. Among them, rosuvastatin The statin group took rosuvastatin according to the instructions, and the simvastatin group took simvastatin according to the instructions for use. The course of treatment was 8 weeks. Before and after treatment, total cholesterol (TC), triglyceride (TG), high density Lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C) levels and liver and kidney function. Results After 8 weeks of treatment, 38 cases were effective in rosuvastatin group, 54 cases were effective, 8 cases were ineffective, and the total effective rate was 92.0%. In simvastatin group, 30 cases were markedly effective, 50 cases were effective and 20 cases were ineffective. The total effective rate was 80.0%. The total effective rate of lipid lowering between the two groups was statistically significant (P <0.05). Conclusion Rosuvastatin is more effective than simvastatin in lowering blood fat and has similar adverse reactions, which has high clinical value.